Rx-to-OTC Switches Market
Market Insights on Rx-to-OTC Switches covering sales outlook, demand forecast & up-to-date key trends
Rx to OTC Switch Market by Drug Category (Allergy and Respiratory, Fungal Infections & Other Infections, Overactive Bladder, Oral Contraceptives, Gastrointestinal Drugs, Hair Loss Treatments), Distribution Channel & Region - Forecast to 2021-2031
Rx-to-OTC Switches Market Snapshot
Rx-to-OTC switches sales value is estimated to total US$ 35 Bn in 2021, according to a Future Market Insights (FMI) study. Exhibiting 5.3% CAGR, the overall Rx-to-OTC switches market size is likely to surpass US$ 58 Bn by 2031.
Despite a period of tepid sales, growth will recover at a year on year rate of 5.2% in 2021. The demand for allergy and respiratory drugs is expected to increase at an accelerated pace in the coming decade. As per FMI analysis, allergy and respiratory drugs segment will account for 26.7% of the Rx-to-OTC switches market in 2021.
Let us know your requirement to get
100% FREE customization
Key Points Covered in Rx-to-OTC Switches Market Study
- Market estimates and forecast 2016-2031
- Key drivers and restraints impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Rx-to-OTC Switches Market and How to Navigate
- Recommendation on Key Winning Strategies
2016-2020 Rx-to-OTC Switches Market Outlook Compared to 2021-2031 Forecast
According to Future Market Insights (FMI), the sales of Rx-to-OTC switched products have grown at a 1.5% CAGR between 2016 and 2020. Rx-to-OTC switch products are the transition of proven prescription drugs to nonprescription, over-the-counter (OTC) status. It is a strict and highly regulated process that allows consumers to gain OTC access to a growing range of medicines for treating common diseases like headache, cold and flu, and cough, among others.
Rx to OTC switch is gaining popularity as one of the best ways to provide cost-effective, first-line treatment for common illnesses like cough, cold, flu, and headache. Many patients do not have time to visit the doctors or the physicians they mainly prefer quick access to OTC medicines.
As OTC products are widely available in pharmacies, the delayed physician supervision has lowered the demand for prescription drugs to treat common diseases. Considerably, the rising demand for OTC over prescription products has led many pharmaceutical companies to assume that the switches would contribute significantly to OTC revenue growth in the near future.
Key markets such as the U.S., India, and China, have significant untapped potential for the expansion of Rx-to-OTC switches market. Growth in research and development (R&D) capabilities to meet the global demand for OTC medicines over the prescription will aid the expansion of the market. Small and large pharmaceutical companies are focusing on the Rx to OTC switch owing to the rising OTC demand over prescription drugs.
.jpg "Rx-to-OTC Switches Market")
Various safety studies are undertaken to comply with Food and Drug Administration (FDA) requirements, which are intended to improve efficacy and safety of drug available over the counter. These regulations will also help in preventing misuse and abuse of OTC drugs.
After a long period of drought in the year 2018 and 2019, in 2020 FDA approved three Rx-to-OTC switch produts including Pataday Twice Daily Relief (ophthalmic solution/drops), Voltaren Arthritis Pain (topical gel), and Pataday Once Daily Relief (ophthalmic solution/drops) for OTC use. Such approvals will continue aiding growth in the market.
Future Market Insights forecasts the global Rx-to-OTC switches market to rise at 5.3 % CAGR between 2021 and 2031.
What are the Leading Opportunities for Market Growth?
Patient compatibility and safety for self-medication are key concerns among pharmaceutical companies. Manufacturers are focusing on patient centricity to ensure long-term success by offering safety and high potential products that will attract consumers. They are exploring opportunities for manufacturers in the market.
The past decade has witnessed a decline in Rx-to-OTC switches with only one switch, including 2010, 2011, and 2015 and zero switches in the year 2018 and 2019. While in 2020 there was increase in the switches owing to the growing demand for OTC products which is expected to continue in 2021.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow will Regulations on Healthcare Sector Impact Rx-to-OTC Switches?
The regulatory burden associated with multiple clearance procedures under FDA’s scientific decisions to a nimble “administrative order” process within agencies, speeding up decisions considerably, is key to requisite infrastructure.
OTC products should demonstrate an adequate safety and efficacy profile to meet the FDA’s approval standards. Evidence of safety, correct diagnosis, and treatment of medical conditions with minimal professional supervision makes the approval process complicated.
This creates hesitatance among pharmaceutical companies to invest in the switch market, impeding the growth of the Rx-to-OTC switches market.
For instance, Mevacor® (a cholesterol-lowering statin drug) and Pravachol®(a statin medication), both failed to obtain approval for an Rx-to-OTC switch due to the FDA’s conclusion that patients’ perceptions of their disease and the monitoring necessary for successful disease management were not adequately understood and demonstrated.
Additionally, The COVID-19 pandemic caused a shift in behaviours relating to both prescription and OTC medicines owing to the ease of drug use habits and availability. Although OTC drugs are less potent than other substances, they still pose a risk of addiction. Lack of awareness can cause incorrect self-diagnosis, complications, and associated adverse effects.
What is the Impact of the COVID-19 Crisis on Rx-to-OTC Switches Sales?
The OTC consumer health sector has been a key focus of pharmaceutical companies recently, especially after the pandemic arrived in 2020. In 2020, numerous prescription (Rx) medicines switched to OTC status. These include pharmaceutical companies such as GlaxoSmithKline plc, Alcon Laboratories Inc. and some Asian pharmaceutical companies including Lupin and Cipla.
After a long period of wait, FDA approved the Rx-to-OTC switch of 3 prescription products. With the Covid-19 pandemic intensifying, it is expected that the focus on OTC products will continue to strengthen because visits to doctors are restricted.
Consequently, the sales of Rx to OTC switch products was seen to increase in 2020. There was a positive impact on market growth which is expected to drive sales across the forecast period as well.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Country-wise Insights
How Lucrative is the Opportunity for Manufacturers in the U.S?
The U.S. holds over 75% share of the Rx-to-OTC switches market in North America. In the U.S., the research collaboration and approvals for prescription switched drugs are key to market developments.
Based on recent switches, the FDA seems to follow a more conservative path in approving traditional types of OTC products used for self-limiting, acute, non-life-threatening conditions with readily recognizable symptoms that consumers can identify. However, the FDA tends to approve products for preventing chronic conditions like asthma or heart disease.
Moreover, after a long period of decline in approvals, in 2020, FDA approved the Rx-to-OTC switch of three prescription drugs. However, expansion strategies implemented by pharmaceutical companies seeking approval is progress towards providing consumers access to an effective treatment.
For instance, In February 2020, GSK received FDA approval for Voltaren Arthritis Pain as an OTC product to temporarily relieve arthritis pain, which is commercially available in the U.S.
What are the Favorable Policies Driving Growth of Rx-to-OTC Switches in the U.K.?
The U.K. market will account for over 33% of the Europe market through the assessment period ending in 2031. The U.K. Pharmacy Minister Earl Howe has continually stressed that considering the patient's demand for access of ease of availability, medicines without a prescription is a priority for the British government.
Outside the regulatory systems of the EU, the MHRA is focusing on exploring different pathways to Rx-to-OTC switches.Currently, the UK government is focusing on reviewing plans for all opioid-containing medicines sold in the country to carry on-pack addiction warnings which is manipulating the demand for OTC products.
What are the Key Factors Enabling Growth in Germany?
The Germany market will exhibit a 5.0% CAGR throughout the forecast period. Regulatory guidelines are relatively strict in Germany. As a result, achieving drug approvals for Rx-OTC switch assistance is a complex procedure in the country. Germany is the second leading market in Europe due to the presence of leading manufacturers enhancing the R&D capabilities.
For instance, Merck Co. Ltd. A German-based pharmaceutical company invested around €18 million at its site in Tempe, Arizona located U.S. This investment would provide flexibility to invest in its production facilities and strengthen its R&D capabilities in its global network.
What is the Scope of growth of Rx-to-OTC Switches Sales in the India Market?
The Indian market accounted for more than 33% of the sales registered in the South Asia region in 2021. India ranks as the 11th largest OTC drug market globally and is counted amongst one of the most lucrative markets globally. Indian pharma companies have a significant edge over their counterparts, influenced by the consumer’s needs.
The Indian pharma companies are shifting their focus to a less-explored market, i.e. OTC drugs to reduce dependency on other countries for APIs and raw materials. Recent developments have given rise to new buying trends. Consumer preference towards Made in India tagged drugs are expected to flourish in the post-pandemic era.
Thus increasing disposable income along with a shift in consumer attitude toward the cost-effectiveness- in self-medication has significantly propelled the demand for Rx-to-OTC switches in the country.
What are the Factors Driving Revenue Generation in the China market?
The market for Rx-to-OTC switches in China is exhibiting 8.0% CAGR and is expected to account for more than 45% of the East Asia market throughout the projection period. Large emerging markets, especially in China have a great opportunity in expansion towards Rx-to-OTC switches.
As China has no market exclusivity for R&D capacity of Rx-to-OTC switches, any leading pharmaceutical company can manufacture and commercialize in the region once the switch sponsor has received approval from the SFDA.
Category-wise Insights
How are Allergy and Respiratory Drugs Contributing to Revenue?
Allergy and respiratory drugs have a higher potential for growth in the coming years. The segment is likely to grow with a high CAGR of 5.7% in the coming decade. Antihistamines are the first approved Rx-to-OTC switched drugs that have the potential to treat lifestyle-based ailments and has gained popularity in the market. For example, OTC antihistamine eye drops relieve red itchy eyes, while nasal sprays can be used to treat the symptoms of seasonal or year-round allergies.
What is the Scope of Growth for Retail Pharmacies in the Market?
Retail pharmacies are currently leading the market, with significant growth in the Rx-to-OTC Switches market with a 5.1% CAGR in the forecast period. Retail pharmacies have made possible the availability of OTC drugs to treat numerous ailments without healthcare professional in high stocks and cost-effective prices. Pharmacists played a vital role in controlling the number of medications being dispensed as OTC drugs.
Competitive Landscape
Participants in the Rx-to-OTC switches market are primarily aiming for strategic collaborations and R&D investments to consolidate growth in a competitive and fragmented market. With this, pharmaceutical companies are also engaged in expanding their global and regional presence through acquisitions, expansions, product launches and improvement of distribution channels to penetrate the new regional markets.
- For Instance, In April 2021, Pfizer Inc. acquired Amplyx Pharmaceuticals, Inc., a privately-held pharmaceutical company.
- In June 2021, FDA approved Rx-to-OTC switch for Astepro allergy nasal spray, which will be liableble at mass retail locations across the U.S.
- In January 2021, Viagra will be available to consumers in Ireland via OTC channels following a successful switch procedure, with a simple pharmacist consultation.
Scope of the Report
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Market Analysis |
USD Million for Value in Million |
|
Key Countries Covered |
US, Canada, U.K., Germany, Italy, France, Spain, Benelux, Russia, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, Turkey, South Africa and North Africa |
|
Key Segments Covered |
Drug Category, Distribution Channel, and Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
Rx to OTC Switch Market by Category
Drug Category
- Allergy and Respiratory
- Fungal Infections & Other Infections
- Overactive Bladder
- Oral Contraceptives
- Gastrointestinal Drugs
- Hair Loss Treatments
- Smoking Cessation
- Analgesic, Inflammation And Pain Management
- Others (Lice, Acne, Weight Loss, And Laxative)
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa (MEA)
Frequently Asked Questions
The Rx-to-OTC switches market will be worth US$ 35 Bn in the year 2021 and is expected to reach US$ 58 Bn by 2031 owing to growing demand for OTC over prescribed drugs.
Response: The Rx-to-OTC switches market is estimated to grow at a CAGR of 5.3% during the forecast period with an estimated Rx-to-OTC switched products revenue accounting more than US$ 58 Bn in 2031.
Historically, the market has grown at a CAGR of 1.5% in the last 5 years, between 2016 and 2020.
Altering the dosage form of the prescribed drugs to extend its life-cycle, offering patient centric products with increased customization, higher approval for the modified products to treat new indications, and adoption of strategic agreements by key market leaders are some of the key trends adopted by the manufacturers.
Growing preference for OTC drugs over prescribed drugs, rising demand for accessible and varied treatment options, are some of the driving factors that has bolstered the demand in the market.
The cumulative market share of top 3 players including GlaxoSmithKline Plc, Sanofi, and Johnson & Johnson constitute over 46% of the overall market.
The U.S., U.K., Germany, China, and India are the top 5 countries that are driving the demand for Rx-to-OTC switches market.
North America holds more than 26% revenue share in the overall Rx-to-OTC switches market in 2021. Rising approvals and presence of key players in the market are driving the demand for Rx-to-OTC switches in the region.
The Europe market is set to exhibit a CAGR of 4.7% during the forecast period.
The U.S., India, Germany, U.K. and China are some of the key producers in the Rx-to-OTC switches market.
GlaxoSmithKline Plc., Sanofi, Johnson & Johnson, Pfizer Inc., AstraZeneca, Merck KGaA , and Bayer AG are some of the key exporters of the Rx-to-OTC switches market.
Japan has emerged as a key market, exhibiting growth at 6.7% during the forecast period. South Korea will account for 16.8% of the East Asia Rx-to-OTC switches market in 2021.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Healthcare Outlook
4.1.3. Per Capita Healthcare Expenditure Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. Growing Demand and Sales for OTC Medication
4.2.2. Cost of OTC Medication
4.2.3. Availability of OTC Drugs
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity Analysis
5. COVID19 Crisis Analysis
5.1. Current COVID19 Probable Future Impact
5.2. Current GDP Projection and Probable Impact
5.3. Current Economic Projection as compared to 2008 Economic analysis
5.4. COVID19 and Impact Analysis
5.4.1.1. Revenue By Drug Categories
5.4.1.2. Revenue By Distribution Channel
5.4.1.3. Revenue By Region
5.5. 2020 Market Scenario
5.6. Recovery Scenario – Short term, Midterm and Long Term Impact
6. Key Success Factors
6.1. Business Model
6.2. Key Regulations
6.3. Go-To-Market Strategy
6.4. Adoption Rate of OTC drugs, By Region
7. Global Rx-to-OTC Switches Market Demand (in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Drug Category
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug Category, 2016–2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Category, 2021-2031
8.3.1. Allergy and Respiratory
8.3.2. Fungal Infections & Other infections
8.3.3. Overactive Bladder
8.3.4. Oral Contraceptives
8.3.5. Gastrointestinal Drugs
8.3.6. Hair Loss Treatments
8.3.7. Smoking Cessation
8.3.8. Analgesic, Inflammation and pain management
8.3.9. Others (lice, Acne, weight loss, laxative)
8.4. Market Attractiveness Analysis By Drug Category
9. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016–2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Drug Stores
9.3.4. Online Pharmacies
9.4. Market Attractiveness Analysis By Distribution Channel
10. Global Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016–2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. Middle East & Africa
10.4. Market Attractiveness Analysis By Region
11. North America Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug Category
11.3.3. By Distribution Channel
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Latin America Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Category
12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Europe Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Drug Category
13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. East Asia Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
14.3. Current and Future Market Size (US$ Mn) Trend and Analysis and Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Drug Category
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. South Asia Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Drug Category
15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Oceania Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug Category
16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
17. Middle East and Africa Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. Northern Africa
17.3.1.4. South Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Drug Category
17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
18. Key and Emerging Countries Rx-to-OTC Switches Market Analysis 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. U.S. Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.2.1. By Drug Category
18.2.2. By Distribution Channel
18.3. Canada Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.3.1. By Drug Category
18.3.2. By Distribution Channel
18.4. Mexico Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.4.1. By Drug Category
18.4.2. By Distribution Channel
18.5. Brazil Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.5.1. By Drug Category
18.5.2. By Distribution Channel
18.6. U.K. Rx-to-OTC Switches Market Value (US$) Analysis, 2021 & 2031
18.6.1. By Drug Category
18.6.2. By Distribution Channel
18.7. Germany Rx-to-OTC Switches Market Analysis
18.7.1. By Drug Category
18.7.2. By Distribution Channel
18.8. France Rx-to-OTC Switches Market Analysis
18.8.1. By Drug Category
18.8.2. By Distribution Channel
18.9. Italy Rx-to-OTC Switches Market Analysis
18.9.1. By Drug Category
18.9.2. By Distribution Channel
18.10. Spain Rx-to-OTC Switches Market Analysis
18.10.1. By Drug Category
18.10.2. By Distribution Channel
18.11. Russia Rx-to-OTC Switches Market Analysis
18.11.1. By Drug Category
18.11.2. By Distribution Channel
18.12. China Rx-to-OTC Switches Market Analysis
18.12.1. By Drug Category
18.12.2. By Distribution Channel
18.13. Japan Rx-to-OTC Switches Market Analysis
18.13.1. By Drug Category
18.13.2. By Distribution Channel
18.14. South Korea Rx-to-OTC Switches Market Analysis
18.14.1. By Drug Category
18.14.2. By Distribution Channel
18.15. India Rx-to-OTC Switches Market Analysis
18.15.1. By Drug Category
18.15.2. By Distribution Channel
18.16. Thailand Rx-to-OTC Switches Market Analysis
18.16.1. By Drug Category
18.16.2. By Distribution Channel
18.17. Indonesia Rx-to-OTC Switches Market Analysis
18.17.1. By Drug Category
18.17.2. By Distribution Channel
18.18. Malaysia Rx-to-OTC Switches Market Analysis
18.18.1. By Drug Category
18.18.2. By Distribution Channel
18.19. Australia Rx-to-OTC Switches Market Analysis
18.19.1. By Drug Category
18.19.2. By Distribution Channel
18.20. New Zealand Rx-to-OTC Switches Market Analysis
18.20.1. By Drug Category
18.20.2. By Distribution Channel
18.21. GCC Countries Rx-to-OTC Switches Market Analysis
18.21.1. By Drug Category
18.21.2. By Distribution Channel
18.22. South Africa Rx-to-OTC Switches Market Analysis
18.22.1. By Drug Category
18.22.2. By Distribution Channel
18.23. Turkey Rx-to-OTC Switches Market Analysis
18.23.1. By Drug Category
18.23.2. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Concentration
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive
20.2.1. GlaxoSmithKline plc.
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. Profitability by Market Segments (Product/Channel/Region)
20.2.1.4. Sales Footprint
20.2.1.5. Strategy Overview
20.2.1.5.1. Marketing Strategy
20.2.1.5.2. Product Strategy
20.2.1.5.3. Channel Strategy
20.2.2. Astrazeneca
20.2.2.1. Overview
20.2.2.2. Product Portfolio
20.2.2.3. Profitability by Market Segments (Product/Channel/Region)
20.2.2.4. Sales Footprint
20.2.2.5. Strategy Overview
20.2.2.5.1. Marketing Strategy
20.2.2.5.2. Product Strategy
20.2.2.5.3. Channel Strategy
20.2.3. Merck KGaA
20.2.3.1. Overview
20.2.3.2. Product Portfolio
20.2.3.3. Profitability by Market Segments (Product/Channel/Region)
20.2.3.4. Sales Footprint
20.2.3.5. Strategy Overview
20.2.3.5.1. Marketing Strategy
20.2.3.5.2. Product Strategy
20.2.3.5.3. Channel Strategy
20.2.4. Johnson & Johnson
20.2.4.1. Overview
20.2.4.2. Product Portfolio
20.2.4.3. Profitability by Market Segments (Product/Channel/Region)
20.2.4.4. Sales Footprint
20.2.4.5. Strategy Overview
20.2.4.5.1. Marketing Strategy
20.2.4.5.2. Product Strategy
20.2.4.5.3. Channel Strategy
20.2.5. Bayer AG
20.2.5.1. Overview
20.2.5.2. Product Portfolio
20.2.5.3. Profitability by Market Segments (Product/Channel/Region)
20.2.5.4. Sales Footprint
20.2.5.5. Strategy Overview
20.2.5.5.1. Marketing Strategy
20.2.5.5.2. Product Strategy
20.2.5.5.3. Channel Strategy
20.2.6. Sanofi
20.2.6.1. Overview
20.2.6.2. Product Portfolio
20.2.6.3. Profitability by Market Segments (Product/Channel/Region)
20.2.6.4. Sales Footprint
20.2.6.5. Strategy Overview
20.2.6.5.1. Marketing Strategy
20.2.6.5.2. Product Strategy
20.2.6.5.3. Channel Strategy
20.2.7. Boehringer Ingelheim Consumer Healthcare
20.2.7.1. Overview
20.2.7.2. Product Portfolio
20.2.7.3. Profitability by Market Segments (Product/Channel/Region)
20.2.7.4. Sales Footprint
20.2.7.5. Strategy Overview
20.2.7.5.1. Marketing Strategy
20.2.7.5.2. Product Strategy
20.2.7.5.3. Channel Strategy
20.2.8. Bausch and Lomb (A Subsidiary of Bausch Health)
20.2.8.1. Overview
20.2.8.2. Product Portfolio
20.2.8.3. Profitability by Market Segments (Product/Channel/Region)
20.2.8.4. Sales Footprint
20.2.8.5. Strategy Overview
20.2.8.5.1. Marketing Strategy
20.2.8.5.2. Product Strategy
20.2.8.5.3. Channel Strategy
20.2.9. Galderma SA
20.2.9.1. Overview
20.2.9.2. Product Portfolio
20.2.9.3. Profitability by Market Segments (Product/Channel/Region)
20.2.9.4. Sales Footprint
20.2.9.5. Strategy Overview
20.2.9.5.1. Marketing Strategy
20.2.9.5.2. Product Strategy
20.2.9.5.3. Channel Strategy
20.2.10. Alcon
20.2.10.1. Overview
20.2.10.2. Product Portfolio
20.2.10.3. Profitability by Market Segments (Product/Channel/Region)
20.2.10.4. Sales Footprint
20.2.10.5. Strategy Overview
20.2.10.5.1. Marketing Strategy
20.2.10.5.2. Product Strategy
20.2.10.5.3. Channel Strategy
20.2.11. Arbor Pharmaceuticals
20.2.11.1. Overview
20.2.11.2. Product Portfolio
20.2.11.3. Profitability by Market Segments (Product/Channel/Region)
20.2.11.4. Sales Footprint
20.2.11.5. Strategy Overview
20.2.11.5.1. Marketing Strategy
20.2.11.5.2. Product Strategy
20.2.11.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Drug Category
Table 02: Global Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel
Table 03: Global Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Region
Table 04: North America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 05: North America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category
Table 06: North America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Distribution Channel
Table 07: Latin America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 08: Latin America Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category
Table 09: Latin America Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel
Table 10: Europe Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 11: Europe Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category
Table 12: Europe Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel
Table 13: East Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 14: East Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category
Table 15: East Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel
Table 16: South Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 17: South Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category
Table 18: South Asia Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel
Table 19: Oceania Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 20: Oceania Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category
Table 21: Oceania Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel
Table 22: Middle East & Africa Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 23: Middle East & Africa Rx-to-OTC Switches Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Category
Table 24: Middle East & Africa Rx-to-OTC Switches Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Rx-to-OTC Switches Market size (US$ Mn) 2021E & 2031F
Figure 02: Global Rx-to-OTC Switches Market Value Share, by Drug Category 2020 (A)
Figure 03: Global Rx-to-OTC Switches Market Value Share, by Distribution Channel 2020 (A)
Figure 04: Global Rx-to-OTC Switches Market Value Share, by Region 2020 (A)
Figure 05: Global Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 06: Global Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 - 2031
Figure 07: Global Rx-to-OTC Switches Market Absolute $ Opportunity, 2021 - 2031
Figure 08: Global Rx-to-OTC Switches Market Share Analysis (%), By Drug Category, 2021& 2031
Figure 09: Global Rx-to-OTC Switches Market Y-o-Y Analysis (%), By Drug Category, 2021- 2031
Figure 10: Global Rx-to-OTC Switches Market Attractiveness Analysis By Drug Category, 2021 & 2031
Figure 11: Global Rx-to-OTC Switches Market Share Analysis (%), By Distribution Channel, 2021& 2031
Figure 12: Global Rx-to-OTC Switches Market Y-o-Y Analysis (%), By Distribution Channel, 2021 - 2031
Figure 13: Global Rx-to-OTC Switches Market Attractiveness Analysis By Distribution Channel, 2021& 2031
Figure 14: Global Rx-to-OTC Switches Market Share Analysis (%), By Country, 2021& 2031
Figure 15: Global Rx-to-OTC Switches Market Y-o-Y Analysis (%), By Country, 2021& 2031
Figure 16: Global Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021- 2031
Figure 17: North America Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)
Figure 18: North America Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)
Figure 19: North America Rx-to-OTC Switches Market Value Share By Country 2021 (E)
Figure 20: North America Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 21: North America Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021- 2031
Figure 22: North America Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021 -2031
Figure 23: North America Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021 - 2031
Figure 24: North America Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021 - 2031
Figure 25: Latin America Rx-to-OTC Switches Market Value Share By Application 2021 (E)
Figure 26: Latin America Rx-to-OTC Switches Market Share By Distribution Channel 2021 (E)
Figure 27: Latin America Rx-to-OTC Switches Market Value Share By Country 2021 (E)
Figure 28: Latin America Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 29: Latin America Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 & 2031
Figure 30: Latin America Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021 - 2031
Figure 31: Latin America Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021 - 2031
Figure 32: Latin America Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021 - 2031
Figure 33: Europe Rx-to-OTC Switches Market Value Share, By Drug Category 2021 (E)
Figure 34: Europe Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)
Figure 35: Europe Rx-to-OTC Switches Market Value Share By Country 2021 (E)
Figure 36: Europe Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 37: Europe Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 & 2031
Figure 38: Europe Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021 - 2031
Figure 39: Europe Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021 - 2031
Figure 40: Europe Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021 - 2031
Figure 41: East Asia Rx-to-OTC Switches Market Value Share, By Drug Category 2021 (E)
Figure 42: East Asia Rx-to-OTC Switches Market Value Share, By Distribution Channel 2021 (E)
Figure 43: East Asia Rx-to-OTC Switches Market Value Share, By Country 2021 (E)
Figure 44: East Asia Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 45: East Asia Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021 -2031
Figure 46: East Asia Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031
Figure 47: East Asia Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031
Figure 48: East Asia Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031
Figure 49: South Asia Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)
Figure 50: South Asia Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)
Figure 51: South Asia Rx-to-OTC Switches Market Value Share By Country 2021 (E)
Figure 52: South Asia Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 53: South Asia Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021& 2031
Figure 54: South Asia Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031
Figure 55: South Asia Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031
Figure 56: South Asia Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031
Figure 57: Oceania Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)
Figure 58: Oceania Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)
Figure 59: Oceania Rx-to-OTC Switches Market Value (US$ Mn) & Forecast 2021& 2031
Figure 60: Oceania Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 61: Oceania Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021& 2031
Figure 62: Oceania Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031
Figure 63: Oceania Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031
Figure 64: Oceania Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031
Figure 65: Middle East & Africa Rx-to-OTC Switches Market Value Share By Drug Category 2021 (E)
Figure 66: Middle East & Africa Rx-to-OTC Switches Market Value Share By Distribution Channel 2021 (E)
Figure 67: Middle East & Africa Rx-to-OTC Switches Market Value Share By Country 2021 (E)
Figure 68: Middle East & Africa Rx-to-OTC Switches Market Value Analysis (US$ Mn), 2016-2020
Figure 69: Middle East & Africa Rx-to-OTC Switches Market Value Forecast (US$ Mn), 2021& 2031
Figure 70: Middle East & Africa Rx-to-OTC Switches Market Attractiveness Analysis by Drug Category, 2021-2031
Figure 71: Middle East & Africa Rx-to-OTC Switches Market Attractiveness Analysis by Distribution Channel, 2021-2031
Figure 72: Middle East & Africa Rx-to-OTC Switches Market Attractiveness Analysis by Country, 2021-2031
Figure 73: Global Rx-to-OTC Switches Market Value Proportion Analysis, By Key Countries, 2021 (E)
Figure 74: Rx-to-OTC Switches Market , Global Vs. Country Growth Y-o-Y (%) Comparison, 2021-2031
Figure 75: U.S. Market Value Proportion Analysis
Figure 76: Global Vs U.S. Growth Comparison
Figure 77: U.S. Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 78: U.S. Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 79: Canada Market Value Proportion Analysis
Figure 80: Global Vs Canada Growth Comparison
Figure 81: Canada Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 82: Canada Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 83: Mexico Market Value Proportion Analysis
Figure 84: Global Vs Mexico Growth Comparison
Figure 85: Mexico Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 86: Mexico Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 87: Brazil Market Value Proportion Analysis
Figure 88: Global Vs Brazil Growth Comparison
Figure 89: Brazil Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 90: Brazil Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 91: U.K. Market Value Proportion Analysis
Figure 92: Global Vs U.K. Growth Comparison
Figure 93: U.K. Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 94: U.K. Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 95: Germany Market Value Proportion Analysis
Figure 96: Global Vs Germany Growth Comparison
Figure 97: Germany Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 98: Germany Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 99: France Market Value Proportion Analysis
Figure 100: Global Vs France Growth Comparison
Figure 101: France Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 102: France Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 103: Italy Market Value Proportion Analysis
Figure 104: Global Vs Italy Growth Comparison
Figure 105: Italy Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 106: Italy Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 107: Spain Market Value Proportion Analysis
Figure 108: Global Vs Spain Growth Comparison
Figure 109: Spain Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 110: Spain Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 111: Russia Market Value Proportion Analysis
Figure 112: Global Vs Russia Growth Comparison
Figure 113: Russia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 114: Russia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 115: China Market Value Proportion Analysis
Figure 116: Global Vs China Growth Comparison
Figure 117: China Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 118: China Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 119: Japan Market Value Proportion Analysis
Figure 120: Global Vs Japan Growth Comparison
Figure 121: Japan Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 122: Japan Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 123: South Korea Market Value Proportion Analysis
Figure 124: Global Vs South Korea Growth Comparison
Figure 125: South Korea Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 126: South Korea Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 127: India Market Value Proportion Analysis
Figure 128: Global Vs India Growth Comparison
Figure 129: India Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 130: India Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 131: Thailand Market Value Proportion Analysis
Figure 132: Global Vs Thailand Growth Comparison
Figure 133: Thailand Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 134: Thailand Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 135: Indonesia Market Value Proportion Analysis
Figure 136: Global Vs Indonesia Growth Comparison
Figure 137: Indonesia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 138: Indonesia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 139: Malaysia Market Value Proportion Analysis
Figure 140: Global Vs Malaysia Growth Comparison
Figure 141: Malaysia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 142: Malaysia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 143: Australia Market Value Proportion Analysis
Figure 144: Global Vs Australia Growth Comparison
Figure 145: Australia Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 146: Australia Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 147: New Zealand Market Value Proportion Analysis
Figure 148: Global Vs New Zealand Growth Comparison
Figure 149: New Zealand Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 150: New Zealand Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 151: GCC Countries Market Value Proportion Analysis
Figure 152: Global Vs GCC Countries Growth Comparison
Figure 153: GCC Countries Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 154: GCC Countries Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 155: South Africa Market Value Proportion Analysis
Figure 156: Global Vs South Africa Growth Comparison
Figure 157: South Africa Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 158: South Africa Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Figure 159: Turkey Market Value Proportion Analysis
Figure 160: Global Vs Turkey Growth Comparison
Figure 161: Turkey Rx-to-OTC Switches Market Share Analysis, By Drug Category, 2020 & 2031
Figure 162: Turkey Rx-to-OTC Switches Market Share Analysis, By Distribution Channel, 2020 & 2031
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
